Lisa Ebert
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Associate Professor Lisa Ebert is a Group Leader in the Translational Oncology Laboratory at the Centre for Cancer Biology (https://www.centreforcancerbiology.org.au/research/laboratories/translational-oncology-laboratory). She also holds positions of Affiliate Senior Lecturer of the University of Adelaide (Adelaide Medical School) and Adjunct Associate Research Professor at the University of South Australia.
A/Prof Ebert directs a research program focused on T cell-based cancer immunotherapies:
- Chimeric antigen receptor (CAR)-T cell therapies: our studies range from the identification of new target antigens, to the design, manufacturing and testing of novel CAR-T cell therapies, and all the way to clinical trials.
- Immune Checkpoint Inhibitor therapies: we use patient blood and tissue specimens to better understand the mechanism of action of these novel agents, with the hope of improving the number of patients that can benefit, and to predict upfront those patients who will respond best to treatment.
A/Prof Ebert's research team sits within The Translational Oncology Laboratory, a diverse group with a focus on developing new and better therapies for cancer, and the translation of these research discoveries to the clinic. The head of the group, Professor Michael Brown, is a medical oncologist and Director of the Cancer Clinical Trials Unit at the Royal Adelaide Hospital. Thus, we are perfectly positioned to study human cancer and to adopt a ‘bench to bedside’ approach for the testing of new therapeutic strategies in the clinic.
Student projects are available in our group for Honours, Masters and PhD.
Some examples of student projects are listed below:
Developing CAR-T cell therapies for brain cancer
Chimeric antigen receptor (CAR)-T cell therapy has revolutionised the treatment of B cell leukaemia and lymphoma, and has spurred intense interest in extending these successes to the treatment of solid tumours, including brain cancers. In clinical trials at the Royal Adelaide Hospital, and in pre-clinical studies using advanced mouse models, we are testing CAR-T cells for their ability to shrink these tumours. We are also interested to understand how effectively these T cells can pass from the blood circulation into tumour tissues, which is where they are required to mediate their cancer cell-killing function, and to to identify ways to enhance CAR-T cell function. Projects are available to address these questions using in vitro functional assays, animal models and analysis of patient blood and tissue samples. These studies are expected to improve our understanding of anti-tumour immunity and ultimately to enhance the efficacy of our clinical CAR-T cell therapies.
Understanding and predicting individual patient responses to Immune Checkpoint Inhibitor (ICI) therapy
ICI therapy is a radical therapeutic approach that is now approved in Australia for the treatment of several cancer types, including melanoma, lung and kidney. These new medicines can re-activate dormant anti-tumour immune responses, leading to dramatic tumour shrinkage, and possibly cure, in a fraction of patients. However, most patients receive little to no benefit, yet are still exposed to the risk of severe side effects. Using pre-treatment blood samples from melanoma patients, we have discovered a way to predict which of these patients will experience significant tumour shrinkage following ICI therapy. Projects are available to further develop this finding, including: (i) using this knowledge to better understand the mechanism of action for ICI therapy; (ii) testing whether this approach also works for patients with other types of cancer; and (iii) translating this discovery into a clinically useful blood test that could be used to ensure that each patient receives the most effective treatment for them.
Location: Centre for Cancer Biology (UniSA Bradley Building – adjacent to AHMS building on North Terrace, Adelaide)
Research project start: Semester 1 or Semester 2
Special requirements: Some vaccinations may be required if handling human specimens
-
Journals
Year Citation 2024 Revesz, I. A., Joyce, P., Ebert, L. M., & Prestidge, C. A. (2024). Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. Clinical and Translational Immunology, 13(2), 16 pages.
2024 Habelrih, T., Ferri, B., Côté, F., Sévigny, J., Augustin, T. L., Sawaya, K., . . . Chemtob, S. (2024). Preventing Preterm Birth: Exploring Innovative Solutions. Clinics in Perinatology, 51(2), 497-510.
Scopus12024 Condon, J. J. J., Trinh, V., Hall, K. A., Reintals, M., Holmes, A. S., Oakden-Rayner, L., & Palmer, L. J. (2024). Impact of Transfer Learning Using Local Data on Performance of a Deep Learning Model for Screening Mammography. Radiology: Artificial Intelligence, 6(4), 10 pages.
Scopus1 Europe PMC12024 Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17.
Scopus5 Europe PMC42024 Gargett, T., & Ebert, L. M. (2024). Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy. Immunology and Cell Biology, 102(7), 535-537.
2024 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
Scopus1 Europe PMC12024 Lertsumitkul, L., Iliopoulos, M., Wang, S. S., McArthur, S. J., Ebert, L. M., Davenport, A. J., . . . Jenkins, M. R. (2024). EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. Journal for ImmunoTherapy of Cancer, 12(8), 1-14.
2023 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2023). Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small, 19(21), 2204956-1-2204956-14.
Scopus3 WoS1 Europe PMC32023 Scheer, K. G., Ebert, L. M., Samuel, M. S., Bonder, C. S., & Gomez, G. A. (2023). Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response. Hypertension, 80(8), 1590-1597.
Scopus12023 Pickering, C., Aiyetan, P., Xu, G., Mitchell, A., Rice, R., Najjar, Y. G., . . . Boland, G. M. (2023). Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Frontiers in Immunology, 14, 14 pages.
Scopus6 Europe PMC32023 Kumari, S., Zemek, R. M., Palendira, U., & Ebert, L. M. (2023). Celebrating 100 years of Immunology & Cell Biology – a special focus on the field of tumor immunology in Australia. Immunology and Cell Biology, 101(9), 783-788.
Scopus12023 Gardam, B., Gargett, T., Brown, M. P., & Ebert, L. M. (2023). Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma. Frontiers in Immunology, 14, 1261257-1-1261257-14.
Scopus5 Europe PMC42023 Stringer, B. W., De Silva, M. I., Greenberg, Z., Noreña Puerta, A., Adams, R., Milky, B., . . . Bardy, C. (2023). Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma. Science Advances, 9(43), eadf1332-1-eadf1332-20.
Scopus2 Europe PMC22023 Myo Min, K. K., Ffrench, C. B., McClure, B. J., Ortiz, M., Dorward, E. L., Samuel, M. S., . . . Bonder, C. S. (2023). Desmoglein-2 as a cancer modulator: friend or foe?. Frontiers in Oncology, 13, 1327478-1-1327478-15.
2022 Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240.
Scopus11 WoS8 Europe PMC102022 Tan, L. Y., Cockshell, M. P., Moore, E., Myo Min, K. K., Ortiz, M., Johan, M. Z., . . . Bonder, C. S. (2022). Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. OncoImmunology, 11(1), e2043673-1-e2043673-18.
Scopus14 WoS5 Europe PMC92022 Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
Scopus16 WoS7 Europe PMC102022 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2022). Nanoparticles targeted to fibroblast activation protein outperform PSMA for MRI delineation of primary prostate tumours.
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
Scopus53 WoS15 Europe PMC402021 Yeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021). The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: Implications for immunotherapy. Cells, 10(3), 1-25.
Scopus43 WoS23 Europe PMC322021 Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(1), 1-14.
Europe PMC72021 Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., . . . Gomez, G. A. (2021). A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. International Journal of Molecular Sciences, 22(9), 4322-1-4322-27.
Scopus28 WoS21 Europe PMC222021 Truong, N. T. H., Gargett, T., Brown, M. P., & Ebert, L. M. (2021). Effects of chemotherapy agents on circulating leukocyte populations: Potential implications for the success of car-t cell therapies. Cancers, 13(9), 19 pages.
Scopus27 WoS15 Europe PMC182021 Martini, C., DeNichilo, M., King, D. P., Cockshell, M. P., Ebert, B., Dale, B., . . . Bonder, C. S. (2021). CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix. BMC Cancer, 21(1), 765-1-765-14.
Scopus18 WoS11 Europe PMC132021 Brown, M. P., Ebert, L. M., & Gargett, T. (2021). Erratum: Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma.. Clinical & translational immunology, 10(8), e1331.
Scopus1 Europe PMC12020 Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
Scopus46 WoS26 Europe PMC302020 Martini, C., Thompson, E. J., Hyslop, S. R., Cockshell, M. P., Dale, B. J., Ebert, L. M., . . . Bonder, C. S. (2020). Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports, 10(1), 5869-1-5869-18.
Scopus20 WoS14 Europe PMC132020 Zadeh Shirazi, A., Fornaciari, E., Bagherian, N. S., Ebert, L. M., Koszyca, B., & Gomez, G. A. (2020). DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images. Medical and Biological Engineering and Computing, 58(5), 1031-1045.
Scopus36 WoS23 Europe PMC192019 Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019). Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochemical Society Transactions, 47(2), 625-638.
Scopus106 WoS85 Europe PMC762019 Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602.
Scopus28 WoS24 Europe PMC252019 Brown, M. P., Ebert, L. M., & Gargett, T. (2019). Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and Translational Immunology, 8(5), 20 pages.
Scopus32 WoS24 Europe PMC262019 Gomez, G. A., Oksdath, M., Brown, M. P., & Ebert, L. M. (2019). New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology. Translational Cancer Research, 8(Suppl. 6), S606-S611.
Scopus9 WoS8 Europe PMC102018 Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401.
Scopus24 WoS20 Europe PMC172017 Davis, I. D., Quirk, J., Morris, L., Seddon, L., Tai, T. Y., Whitty, G., . . . Cebon, J. (2017). A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy, 9(3), 249-259.
Scopus13 WoS11 Europe PMC92017 Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017). Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 6(3), e134-1-e134-9.
Scopus24 WoS21 Europe PMC172016 Ebert, L. M., Tan, L. Y., Johan, M. Z., Min, K. K. M., Cockshell, M. P., Parham, K. A., . . . Bonder, C. S. (2016). A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 19(4), 463-486.
Scopus32 WoS27 Europe PMC232016 Tan, L., Mintoff, C., Johan, M., Ebert, B., Fedele, C., Zhang, Y., . . . Ebert, L. (2016). Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 7(29), 46492-46508.
Scopus40 WoS34 Europe PMC322015 Pitman, M., Powell, J., Coolen, C., Moretti, P., Zebol, J., Pham, D., . . . Pitson, S. (2015). A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 6(9), 7065-7083.
Scopus62 WoS53 Europe PMC432015 Moldenhauer, L., Cockshell, M., Frost, L., Parham, K., Tvorogov, D., Tan, L., . . . Bonder, C. (2015). Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties. Stem Cell Research, 14(3), 380-395.
Scopus16 WoS14 Europe PMC92014 Tan, B., Anaka, M., Deb, S., Freyer, C., Ebert, L., Chueh, A., . . . Mariadason, J. (2014). FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget, 5(1), 264-276.
Scopus44 WoS36 Europe PMC312013 Bonder, C., & Ebert, L. (2013). Fos-icking for control of angiogenesis: Increasing the longevity of peritoneal dialysis. Kidney International, 84(6), 1065-1067.
Scopus5 WoS4 Europe PMC32013 Klein, O., Ebert, L. M., Zanker, D., Woods, K., Tan, B. S., Fucikova, J., . . . Cebon, J. (2013). Flt3 ligand expands CD4⁺FoxP3⁺ regulatory T cells in human subjects. European Journal of Immunology, 43(2), 533-539.
Scopus49 WoS43 Europe PMC342012 Ebert, L. M., MacRaild, S. E., Zanker, D., Davis, I. D., Cebon, J., & Chen, W. (2012). A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS ONE, 7(10), e48424-1-e48424-10.
Scopus51 WoS51 Europe PMC382012 Ebert, L. M., MacRaild, S. E., Davis, I. D., Cebon, J., & Chen, W. (2012). A novel method for detecting antigen-specific human regulatory T cells. Journal of Immunological Methods, 377(1-2), 56-61.
Scopus5 WoS4 Europe PMC32010 Cebon, J., Knights, A., Ebert, L., Jackson, H., & Chen, W. (2010). Evaluation of cellular immune responses in cancer vaccine recipients: Lessons from NY-ESO-1. Expert Review of Vaccines, 9(6), 617-629.
Scopus20 WoS18 Europe PMC172009 Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., . . . Cebon, J. (2009). Melan-a-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research, 15(7), 2507-2513.
Scopus91 WoS82 Europe PMC602009 Nicholaou, T., Ebert, L. M., Davis, I. D., McArthur, G. A., Jackson, H., Dimopoulos, N., . . . Cebon, J. (2009). Regulatory T-Cell-mediated attenuation of T-Cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research, 15(6), 2166-2173.
Scopus110 WoS96 Europe PMC812009 Ebert, L. M., Yu, C. L., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design. Cancer Research, 69(3), 1046-1054.
Scopus49 WoS45 Europe PMC332009 Dimopoulos, N., Jackson, H. M., Ebert, L., Guillaume, P., Luescher, I. F., Ritter, G., & Chen, W. (2009). Combining MHC tetramer and intracellular cytokine staining for CD8<sup>+</sup> T cells to reveal antigenic epitopes naturally presented on tumor cells. Journal of Immunological Methods, 340(1), 90-94.
Scopus15 WoS15 Europe PMC142009 Ebert, L. M., Liu, Y. C., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design (Cancer Research (2009) 69, (1046-54)). Cancer Research, 69(10), 4553.
2008 Ebert, L. M., Bee, S. T., Browning, J., Svobodova, S., Russell, S. E., Kirkpatrick, N., . . . Chen, W. (2008). The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Research, 68(8), 3001-3009.
Scopus169 WoS145 Europe PMC1262006 Schaerli, P., Ebert, L. M., & Moser, B. (2006). Comment on "The vast majority of CLA<sup>+</sup> T cells are resident in normal skin" [1]. Journal of Immunology, 177(3), 1375-1376.
Scopus5 WoS2 Europe PMC22006 Ebert, L. M., Meuter, S., & Moser, B. (2006). Homing and function of human skin γδ T cells and NK cells: Relevance for tumor surveillance. Journal of Immunology, 176(7), 4331-4336.
Scopus208 WoS186 Europe PMC1602006 Nicholaou, T., Ebert, L., Davis, I. D., Robson, N., Klein, O., Maraskovsky, E., . . . Cebon, J. (2006). Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), 303-317.
Scopus101 WoS92 Europe PMC772005 Schaerli, P., Willimann, K., Ebert, L. M., Walz, A., & Moser, B. (2005). Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation. Immunity, 23(3), 331-342.
Scopus124 WoS108 Europe PMC912004 Ebert, L. M., Horn, M. P., Lang, A. B., & Moser, B. (2004). B cells alter the phenotype and function of follicular-homing CXCR5<sup>+</sup> T cells. European Journal of Immunology, 34(12), 3562-3571.
Scopus36 WoS33 Europe PMC322004 Schaerli, P., Ebert, L., Willimann, K., Blaser, A., Roos, R. S., Loetscher, P., & Moser, B. (2004). A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells. Journal of Experimental Medicine, 199(9), 1265-1275.
Scopus189 WoS163 Europe PMC1392002 Ebert, L., & McColl, S. (2002). Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4⁺ T lymphocytes. Journal of Immunology, 168(1), 65-72.
Scopus71 WoS67 Europe PMC482001 Ebert, L., & McColl, S. (2001). Coregulation of CXC chemokine receptor and CD4 expression on T lymphocytes during allogeneic activation. Journal of Immunology, 166(8), 4870-4878.
Scopus40 WoS35 Europe PMC211999 Gale, L., & McColl, S. (1999). Chemokines: extracellular messengers for all occasions?. Bioessays, 21(1), 17-28.
Scopus113 WoS108 Europe PMC80 -
Conference Papers
Year Citation 2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated Desmoglein-2 Surface Expression Is an Independent Predictor of Poor Outcome in Multiple Myeloma. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 24 (pp. S199-S200). CIG MEDIA GROUP, LP. 2005 Ebert, L. M., Schaerli, P., & Moser, B. (2005). Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. In Molecular Immunology Vol. 42 (pp. 799-809). Quebec City, CANADA: PERGAMON-ELSEVIER SCIENCE LTD.
DOI Scopus240 WoS213 Europe PMC1872003 Moser, B., & Ebert, L. (2003). Lymphocyte traffic control by chemokines: Follicular B helper T cells. In Immunology Letters Vol. 85 (pp. 105-112). ELSIMORE, DENMARK: ELSEVIER.
DOI Scopus46 WoS38 Europe PMC27 -
Preprint
Year Citation 2023 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M., Pitson, S., . . . Brown, M. (2023). Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma.
DOI
Current funding sources include NHMRC, Cancer Australia, the Neurosurgical Research Foundation and the Ray & Shirl Norman Cancer Research Trust
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2024 Principal Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Miss Abbey Rose Marshall 2023 Principal Supervisor Investigating the Dendritic Cell - T Cell Axis in Glioblastoma to Explore New Combination Immunotherapy Treatment Options Doctor of Philosophy Doctorate Full Time Mr Bryan James Gardam
Connect With Me
External Profiles